EA2192 / APOLLO
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2, or PALB2 Mutation
Physician and Research Staff Educational Material
This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.
Patient Educational Material
Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material.
Study Chair Kim Reiss, MD of the University of Pennsylvania/Abramson Cancer Center discusses EA2192/APOLLO, a clinical trial for certain patients with pancreatic cancer that has been removed by surgery.
Recruitment/Awareness Promotional Material
Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material. Note: this content can be utilized for site-specific and community outreach (e.g., webpages, informational handouts, posters, etc.) to encourage potential participants to talk with their doctor, or to contact a site where the study is open for more information. The content may not be modified, and the entities who implement this plan (not including clinical staff) must refrain from direct engagement with patients, except to encourage them to speak with their doctor, or to direct them to the trial page on ECOG-ACRIN or Cancer.gov.